CapsoVision Reports Fourth Quarter and Full Year 2025 Financial Results
CapsoVision, Inc. (CV)
Company Research
Source: GlobeNewswire
SARATOGA, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Recent Highlights Fourth quarter 2025 revenue was $3.9 million, a 13% increase over the fourth quarter of 2024. Full year 2025 revenue was $13.6 million, a 15% increase compared to full year 2024.New accounts grew 16% in the fourth quarter of 2025 over the comparable quarter in 2024. Full year 2025 new accounts grew 21% compared to full year 2024.CapsoCam Plus® used by over 161,000 patients as of December 31, 2025.Submitted 510(k) application to the Food and Drug Administration (FDA) for its in-house developed AI-assisted module for CapsoCam Plus®.Completed a $14 million private placement of public equity financing on March 16, 2026. Management Commentary “2025 was a year of important o
Show less
Read more
Impact Snapshot
Event Time:
CV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CV alerts
High impacting CapsoVision, Inc. news events
Weekly update
A roundup of the hottest topics
CV
News
- CapsoVision (CV) had its price target lowered by Benchmark Co. from $14.00 to $10.00. They now have a "speculative buy" rating on the stock.MarketBeat
- CapsoVision Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- CapsoVision, Inc. reports Q4 results [Seeking Alpha]Seeking Alpha
- CapsoVision Conference: CEO Maps AI-Driven Capsule Endoscopy Roadmap for Colon and Pancreas Screening [Yahoo! Finance]Yahoo! Finance
- CapsoVision Announces $14 Million Private Placement Financing [Yahoo! Finance]Yahoo! Finance
CV
Earnings
- 3/26/26 - Miss
CV
Sec Filings
- 3/26/26 - Form 3
- 3/26/26 - Form 10-K
- 3/23/26 - Form 4
- CV's page on the SEC website